Pathologist's health‐care value in the triage of Oncotype DX® testing: a value‐based pathology study of tumour biology with outcomes
Authors:
- 19 June 2018
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 73 (4) , 692-700
Abstract
Aims: Pathologists provide expert tissue assessment of breast cancer, yet their value to guide the appropriate use of breast cancer gene expression profile tests (GEPT) is underutilised. The specific aims of this study are to report morpho‐immunohistological characteristics of breast tumours with Oncotype DX® (ODx) recurrence scores (RS) of 10 or fewer (ultra‐low risk) and 25 or fewer (low risk) in order to determine if pathologists can identify prospectively patient tumours that do not require ODx testing.Methods and results: Oncotype DX® cases with RS < 10 from 2005 to 2010 comprised 441 of 2594 (17%) of clinical cases; this cohort had 5 years’ follow‐up and was treated with endocrine therapy alone. Tumours were analysed for tumour type, Nottingham grade, mitosis score (MS) semi‐quantitative (H‐score) hormone receptor content and Magee equation 3. Knowledge derived from this data set was used to develop algorithms in order to identify prospectively tumours with RS of 10 or fewer or 25 or fewer. Thirty‐four per cent of tumours were low‐grade special types, while the remainder were enriched with high hormone receptor content with MS of 1. These algorithmic selection criteria identified correctly all patient cases below the chemotherapy cut‐point, i.e. RS < 25, indicating that these oncotype test orders were an unnecessary cost.Conclusions: This unique study demonstrates that (i) pathologists add great value to triage breast cancer for GEPT; and (ii) can identify prospectively low‐grade tumour biology with high sensitivity and high specificity for those cases which do not require chemotherapy (RS < 25) using MS and hormone receptor content.Keywords
This publication has 50 references indexed in Scilit:
- Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysisLaboratory Investigation, 2013
- A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomasLaboratory Investigation, 2012
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast CancerJournal of Clinical Oncology, 2011
- Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?Breast Cancer Research and Treatment, 2011
- A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast CancerCancer Investigation, 2010
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?Genetics in Medicine, 2009
- Histopathologic variables predict Oncotype DX™ Recurrence ScoreLaboratory Investigation, 2008
- A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinomaBreast Cancer Research and Treatment, 2007
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004